|Home | About | Journals | Submit | Contact Us | Français|
Simian virus 40 (SV40) is a nonenveloped virus that has been shown to pass from surface caveolae to the endoplasmic reticulum in an apparently novel infectious entry pathway. We now show that the initial entry step is blocked by brefeldin A and by incubation at 20°C. Subsequent to the entry step, the virus reaches a domain of the rough endoplasmic reticulum by an unknown pathway. This intracellular trafficking pathway is also brefeldin A sensitive. Infection is strongly inhibited by expression of GTP-restricted ADP-ribosylation factor 1 (Arf1) and Sar1 mutants and by microinjection of antibodies to βCOP. In addition, we demonstrate a potent inhibition of SV40 infection by the dipeptide N-benzoyl-oxycarbonyl-Gly-Phe-amide, which also inhibits late events in cholera toxin action. Our results identify novel inhibitors of SV40 infection and show that SV40 requires COPI- and COPII-dependent transport steps for successful infection.
Viruses have exploited endocytic pathways to overcome the barrier presented by the plasma membrane and enter animal cells. Although the entry of viruses via clathrin-coated pits has been extensively studied and is well understood (Marsh et al., 1984 ), entry of viruses by alternative pathways has been less well characterized. Simian virus 40 (SV40) is a nonenveloped virus that uses an apparently unique entry route to reach the nucleus of animal cells. SV40 binds to major histocompatibility complex (MHC) class I molecules on the cell surface (Breau et al., 1992 ) and then is observed in tight-fitting, nonclathrin-coated pits (Kartenbeck et al., 1989 ; Anderson et al., 1996 ; Stang et al., 1997 ; Norkin, 1999 ; Parton and Lindsay, 1999 ). These pits are enriched in caveolin-1 but are smaller than caveolae, raising the possibility that caveolin is recruited around the virus (Stang et al., 1997 ). Consistent with this model, the levels of caveolin-1 associated with virus-containing membranes were shown to increase with time (Stang et al., 1997 ). Subsequently, the virus is internalized in a process that is sensitive to cholesterol-perturbing agents (Anderson et al., 1996 ). The role of caveolin in this process is suggested by the finding that viral infection is also inhibited by dominant negative mutants of caveolin (Roy et al., 1999 ). Viral entry apparently occurs without concomitant internalization of MHC class I (Anderson et al., 1998 ), in a process dependent on tyrosine kinase activity (Dangoria et al., 1996 ; Chen and Norkin, 1999 ; Norkin, 1999 ). Early electron microscopic studies suggested that the virus is then transported directly to the endoplasmic reticulum (ER) because no intermediate stations were identified (Kartenbeck et al., 1989 ). A direct pathway between the cell surface and ER would be a novel finding, although parallels can be made to the cholesterol oxidase-induced redistribution of caveolin-1 from caveolae to the lumen of the ER (Smart et al., 1994 ).
The virus eventually reaches the nucleus where uncoating and replication occur. At some stage in the entry pathway the SV40 virions appear to translocate across a membrane into the cytosol and then enter the nucleus via the nuclear pore complexes (Clever et al., 1991 ; Yamada and Kasamatsu, 1993 ). Cytosolic microinjection of antibodies against viral proteins blocks the infection process (Nakanishi et al., 1996 ), suggesting that the virus is actually free in the cytosol at some stage in infection but the mechanism by which translocation into the cytosol occurs, and the compartment involved in this process, are unknown.
Many toxins are retrogradely transported from the cell surface to the ER where translocation into the cytosol occurs. This has provided important insights into the retrograde transport process and the mechanisms involved in translocation. This process has been particularly well characterized for cholera toxin (CT). CT binds via its binding subunits to the ganglioside GM1 at the cell surface. GM1 is slightly enriched in caveolae but is present over the entire cell surface, including clathrin-coated pits (Parton, 1994 ). Inhibitor studies, using cholesterol-disrupting agents, have suggested that CT is internalized via caveolae (Orlandi and Fishman, 1998 ). However, CT is also efficiently internalized, in a cholesterol-dependent process, in cells lacking caveolae (Orlandi and Fishman, 1998 ). Elegant studies using chimeric toxins have shown that association with raft domains is critically important for toxic entry of CT (Wolf et al., 1998 ). Internalization of CT and budding of caveolae have both been proposed to be dynamin dependent (Henley et al., 1998 ; Orlandi and Fishman, 1998 ). After internalization CT passes to endosomes and then the trans-Golgi network. The toxin then arrives at the ER in a process that can be blocked experimentally by brefeldin A (BFA) and by microinjection of coatomer antibodies (Lencer et al., 1993 ; Nambiar et al., 1993 ; Majoul et al., 1998 ; Girod et al., 1999 ). This process is facilitated by a KDEL sequence in the A subunit and retrieval by the KDEL receptor (Majoul et al., 1998 ). On reaching the ER, redox-dependent unfolding of the toxin by protein disulfide isomerase occurs (Tsai et al., 2001 ). The A subunit is then reduced to produce the enzymatically active A1 peptide, which is translocated to the cytosol via the Sec61 channel, identifying the rough ER as the compartment from which translocation occurs (Schmitz et al., 2000 ).
Although recent morphological studies have suggested the involvement of a novel endosomal intermediate, termed a caveosome, in the SV40 entry pathway (Pelkmans et al., 2001 ), the molecular mechanisms directing SV40 along this pathway and the similarities to known trafficking pathways are still unknown. Possible parallels between the SV40 pathway and that of CT are evident with both suggested to involve caveolae, the ER, and then translocation to the cytosol (Parton and Lindsay, 1999 ). This prompted us to examine SV40 infectious entry by using a range of manipulations previously shown to inhibit CT toxicity. We now show that SV40 infection is blocked by BFA, with inhibition at two distinct steps: the initial virus entry step and an intracellular step. Infection is also blocked by a dominant negative ADP-ribosylation factor 1 (Arf1) mutant, by a dominant negative Sar1 mutant, and by microinjection of antibodies to βCOP. These results indicate that SV40 infection either proceeds via a membrane trafficking pathway involving Golgi intermediates or requires a functional exocytic pathway. We compared the effect of these inhibitors of SV40 infection on CT entry and show that CT transport from early endosomes to the Golgi complex is inhibited by both Arf1 and Sar1 mutants. We also show that a novel inhibitor of late events in CT toxicity, the dipeptide N-benzoyl-oxycarbonyl-Gly-Phe-amide (Cbz-gly-phe-NH2), blocks late intracellular steps in SV40 infection, providing new insights into this novel virus entry pathway.
The expression plasmids encoding Arf1(Q71L) (Pepperkok et al., 1998 ; Girod et al., 1999 ), Sar1(H79G) (Aridor et al., 1995 ; Pepperkok et al., 1998 ), and green fluorescent protein (GFP)-tagged temperature-sensitive vesicular stomatitis virus glycoprotein (ts-045-G) (Scales et al., 1997 ), and affinity-purified anti-βCOP (EAGE) (Pepperkok et al., 1993 ) have been described previously. Anti-βCOP (EAGE) antiserum (used for immunofluorescence labeling) and mouse monoclonal antibodies to protein disulfide isomerase (PDI) (Pizarro-Cerda et al., 1998 ) were kind gifts of Drs. Rohan Teasdale and Jenny Stow, respectively (Institute for Molecular Bioscience, Queensland, Australia). Rabbit neutralizing antiserum to SV40 (Butel et al., 1984 ) from Dr. Janet Butel (Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX), affinity-purified anti-p23 (Rojo et al., 1997 ) from Dr. Manuel Rojo (Department of Biochemistry, University of Geneva, Switzerland), human antiserum to EEA1 from Dr. Ban-Hock Toh (Melbourne, Australia), and murine antigiantin (Linstedt and Hauri, 1993 ) from Dr. Hans-Dieter Soeling (Gottingen, Germany) were also generous gifts. Murine monoclonals against caveolin-3 (Transduction Laboratories, Lexington, KY), GM130 (Transduction Laboratories), and SV40 T-antigen (PharMingen, San Diego, CA) were commercially obtained. Brefeldin A, Cbz-gly-phe-NH2, Cbz-gly-gly-NH2, fluorescein isothiocyanate (FITC)-conjugated CT-B subunit, unlabeled holotoxin, and antiserum to CT were obtained from Sigma-Aldrich (St. Louis, MO). 4,6-Diamidino-2-phenylindole (DAPI) and Texas Red-conjugated transferrin were from Molecular Probes (Eugene, OR). Media and cell culture reagents were purchased from Invitrogen (Carlsbad, CA) or BioWhittaker (Walkersville, MD).
Vero cells (African green monkey kidney cells, ATCC CCL 81) and CV1 cells (African green monkey kidney cells, ATCC CCL 70) were maintained in DMEM supplemented with 10% (vol/vol) serum supreme (BioWhittaker) and 2 mM l-glutamine plus or minus penicillin (100 U/ml) and streptomycin (100 μg/ml). Stocks of recombinant Semliki Forest virus (SFV) encoding caveolin-3 (from Dr. Elina Ikonen, National Public Health Institute, Helsinki, Finland) were diluted into serum-free medium containing 2 mM l-glutamine and 0.2% bovine serum albumin before addition to cells. After 1 h of infection at 37°C, cells were washed and infection allowed to proceed for 5 h or more before fixation and immunolabeling for caveolin-3 to detect successfully infected cells. Preparation of SV40-containing supernatant from infected CV1 and Vero cultures and subsequent use of these viral stocks in infection experiments was as described previously (Stang et al., 1997 ). Stocks used to generate SV40 supernatants were a generous gift from Dr. Jurgen Kartenbeck (Division of Cell Biology, German Cancer Research Center, Heidelberg, Germany).
Antibody samples for microinjection were each prepared as previously described in the cited references. Purified rabbit IgG (Sigma-Aldrich) solubilized in 10 mM KH2PO4, pH 7.2, and 75 mM KCl microinjection buffer (Henley et al., 1998 ) was injected at 10 mg/ml as a control. Plasmid DNA for microinjection was purified on a cesium chloride gradient and injected into the nucleus of cells at 50–100 μg/ml. Capillary microinjection of antibodies and DNA into cells was performed using a computer-assisted, automated microinjection system (CompiC INJECT, AIS2; Cellbiology Trading, Hamburg, Germany) by using microcapillaries pulled from thin-wall borosilicate glass capillaries (1.2-mm outer diameter; 0.94-mm inner diameter) (Clark Electromedical Instruments, Pangbourne Reading, England) by a Flaming/Brown P-97 micropipette puller (Sutter, Novato, CA). Cells to be injected were plated onto small glass coverslips and injected at room temperature (RT) in Hanks' medium containing 0.75 mg/ml bicarbonate and 10 mM HEPES, pH 7.4. Cells were allowed to recover for 0.5–4 h postinjection (or 5 h for expression of injected cDNA) in penicillin-streptomycin–containing medium at 37°C before subsequent manipulations.
Experiments requiring immunolabeling with the monoclonal antibody to SV40 T-antigen were fixed in 100% methanol for 5 min at −20°C. Microinjection experiments requiring this fixation were often first fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) at RT for 20 min and subsequently fixed with 100% methanol as described above. This reduced the washing out of the injected antibody by methanol fixation. All other experiments were fixed only with 4% PFA in PBS at RT for 20 min. Processing of cells for immunofluorescence analysis was as follows. PFA-fixed cells were permeabilized in 0.1% saponin in PBS for 10 min before subsequent incubation in 50 mM NH4Cl in PBS for 10 min (to quench aldehyde groups) and in blocking solution (composed of 0.2% bovine serum albumin and 0.2% fish skin gelatin in PBS) for 20 min at RT. A 30-min incubation in blocking solution containing primary antibodies was followed by 4 × 5-min PBS washes before incubation in blocking solution containing fluorescently tagged secondary antibodies for 20 min. After further 4 × 5-min PBS washes, the cells were rinsed in water and mounted in Mowiol mounting medium. In experiments requiring nuclear staining, the cells were incubated in 1 μg/ml DAPI in PBS for 2 min just before rinsing and mounting. Cells fixed with methanol did not require saponin permeabilization. Experiments were viewed and photographed with an Olympus BX60 microscope connected to a Daige charge-couple device camera image capture system. Immunofluorescence images were prepared using Adobe Photoshop 5.0 (Adobe Systems, Mountain View, CA). Cells were processed for electron microscopy according to Stang et al. (1997) .
Infection efficiencies of 20 or more antibody-injected cells and 40 or more transfected cells per experiment were quantified. For drug treatment and temperature-sensitivity experiments, efficiency of infection was quantified from 100 or more cells from each treatment.
SV40 has been shown to be internalized by caveolae and then to reach a subdomain of the ER. The molecular machinery and sorting mechanisms by which the virus reaches the compartment are presently unknown.
We first examined the nature of the SV40-containing compartment by using both plastic sections and immunolabeling. Epon sections of cells incubated with SV40 for 21 h revealed the virus in reticular, smooth-membraned areas of the ER connected to ribosome-studded rough ER membranes (Figure (Figure1,1, A and B). The membrane is closely apposed to the surface of the viral particles, suggesting that the virus remains bound to the lumenal surface of the membrane. Ultrathin frozen sections of these cells were labeled with antibodies to the virus together with antibodies to a cis-Golgi marker, p23, or to a marker of the ER, PDI. The virus-containing membranes were negative for the cis-Golgi/intermediate compartment labeled by antibodies to p23 (our unpublished data) but were labeled by antibodies to PDI (Figure (Figure1C).1C). Although the majority of the virus particles was observed in these very prominent enlarged ER domains, virus particles were occasionally observed in proximity to the Golgi complex, and possibly in Golgi-associated membranes (our unpublished data), raising the possibility that virus may transiently associate with these compartments during infection.
The above-described observations prompted us to further examine the possibility that SV40 passes transiently through the Golgi compartment in a similar manner to many bacterial toxins, which also follow an endocytic route to the ER. Because transient intermediates in infection may be difficult to identify morphologically and the viral infection process is relatively unsynchronized, we chose to use defined membrane trafficking inhibitors together with assays of infection to further delineate the trafficking pathway.
We first examined the possible involvement of the Golgi complex in the SV40 trafficking pathway by using the fungal metabolite BFA. This drug inhibits guanine nucleotide exchange on the small GTPase Arf1 (Jackson and Casanova, 2000 ), an adapter protein responsible for recruitment of COPI coats onto endosomal and biosynthetic membranes. The result is an inhibition of anterograde transport from ER to Golgi complex (Misumi et al., 1986 ) and a concomitant tubulation and fusion of the Golgi with the ER (Lippincott-Schwartz et al., 1989 ; Scheel et al., 1997 ). Consequently, BFA has been widely used to inhibit both anterograde and retrograde transport between the Golgi complex and ER. Vero cells were pretreated for 3 h with BFA and then incubated with SV40 plus BFA for 21 h before fixation and immunolabeling for the virus-encoded T-antigen (T-ag). As shown in Figure Figure2,2, BFA is a potent inhibitor of SV40 infection. With concentrations as low as 0.1 μg/ml we observed 99% inhibition of infection (Figure (Figure2E).2E). These relatively low doses of 0.1 and 0.5 μg/ml BFA were found to be effective in disrupting Golgi morphology within 1 and 3 h of treatment, respectively (Figure (Figure2,2, A and B).
To determine the stage of the infectious entry pathway that was affected by BFA, Vero cells were exposed to a 3-h pulse treatment of 0.1 μg/ml BFA at various time points into SV40 infection at 37°C. Fixation and immunolabeling for T-ag after the 21-h infection period revealed a clear inhibition of SV40 infection when BFA was applied at early stages of viral infection (Figure (Figure2E).2E). To examine the possibility that BFA blocks viral entry, we made use of a neutralizing anti-SV40 antibody, which inactivates surface virus. Addition of the neutralizing antibody to cells incubated with the virus at 4°C with no warming step to allow internalization caused a complete block of infection (our unpublished data). Vero cells cultured in the presence or absence of 0.5 μg/ml BFA for 1 h at 37°C were incubated with SV40 plus or minus BFA on ice for 1 h and then at 37°C for 2 h to allow infection to occur. The cells were then incubated in SV40 neutralizing antibody for 30 min and washed to remove BFA. A further 46 h of infection at 37°C was followed by fixation and immunofluorescence labeling for T-ag. Quantitation of SV40 infection efficiency revealed a substantially greater sensitivity of SV40 infection to the neutralizing antibody in BFA-treated cells compared with untreated cells, indicating a trapping of the virus at the cell surface by BFA (Figure (Figure2F).2F). Thus, it was apparent that the first effect of BFA on SV40 infection was the inhibition of initial viral entry. Consistent with this, treatment with 0.3 μg/ml BFA and incubation with the virus for 21 h showed SV40 immunolabeling only at the periphery of cells, unlike the pattern observed in untreated controls (Figure (Figure2,2, C and D). Dual immunolabeling for caveolin-1 and SV40 revealed no significant colocalization (our unpublished data). Similar results were obtained in cells transiently transfected with caveolin-1-YFP with no colocalization of peripheral SV40 labeling with caveolin-1-YFP (our unpublished data). Epon sections of these cells revealed virus particles in tight-fitting, surface-connected invaginations indistinguishable from those seen in untreated cells at early time points. In accordance with the immunofluorescence data, few virus particles were observed intracellularly (Figure (Figure22G).
To investigate whether BFA also inhibits postsurface trafficking steps, Vero cells were incubated with SV40 for 2 h at 37°C in the absence of BFA to allow viral infection to proceed past the initial internalization step. Any virus remaining at the cell surface was then inactivated with neutralizing antibody and the cells incubated in either the presence or absence of 0.5 μg/ml BFA for the remaining 20 h of infection. Quantitation revealed a strong inhibition of infection in BFA-treated cells compared with untreated controls, showing inhibition of an internal step in SV40 infection (Figure (Figure22H).
We conclude that the initial entry step of SV40 entry is BFA sensitive. In addition, SV40 infection involves a second postentry BFA-sensitive step, possibly involving endosomes and/or the Golgi complex.
Although BFA is best known for its inhibitory effect on transport between ER and Golgi complex, it has also been shown to inhibit early endosome-to-Golgi complex traffic (e.g., of endocytosed Shiga toxin; Mallard et al., 1998 ). To determine whether SV40 is internalized to early endosomes, we made use of the observation that exit from the early endosome is blocked at 20°C (Griffiths et al., 1988 ). Vero cells were infected with SV40 at 20°C for 4 h. Fixation and immunolabeling for the virus revealed a striking loss of staining for the virus (our unpublished data). To confirm this apparent failure of the virus to be internalized at 20°C, we again used the SV40 neutralizing antibody assay. Vero cells were infected with the virus either at 20 or at 37°C for 4 h. Subsequent exposure of the cells to the neutralizing antibody for 30 min was followed by incubation at 37°C for a further 24 h before fixation and immunolabeling for T-ag. Quantitation of infection efficiency revealed a much greater sensitivity of the virus to the neutralizing antibody after a 4-h infection at 20°C than after infection at 37°C (Figure (Figure3).3). We conclude that initial entry of SV40 is sensitive to both BFA and incubation at 20°C.
We next examined the effects of these treatments on a well-characterized retrograde transport pathway. CT is efficiently transported to the ER via the Golgi complex (see INTRODUCTION). We have used either FITC-labeled CT-B (CT-B-FITC), which is transported to the Golgi, or immunolabeling for the holotoxin, which is transported to the ER (Lencer, 2001 ). Vero cells allowed to bind and internalize the FITC-labeled B subunit of the toxin at 20°C showed no inhibition of toxin accumulation in early endosomes (Figure (Figure4,4, A–C). Similarly, Vero cells pretreated for 1 h with 0.5 μg/ml BFA also internalized the toxin to early endosomes (Figure (Figure4,4, D–F). In cells exposed to BFA for a 21-h period comparable with that used in SV40 infection experiments, internalization of CT was still observed, although a greater intensity of plasma membrane fluorescence, possibly indicating a decrease in uptake, was detected (our unpublished data).
Although BFA and a 20°C incubation had little effect on internalization of CT-B, subsequent transport to the Golgi was completely inhibited by both treatments. Even after a 1-h incubation at 20 or 37°C in the presence of BFA, the toxin failed to reach the Golgi (Figure (Figure4,4, A–F). In cells exposed to BFA (Figure (Figure4,4, D–I) the toxin accumulated in sorting endosomes and tubulated recycling endosomes identified by colocalization of cointernalized Texas Red-labeled transferrin with CT-B-FITC (Figure (Figure4,4, G–I). We conclude that the sensitivity of SV40 entry to both BFA and incubation at 20°C is in contrast to other known endocytic pathways, including that of the putative caveolae marker CT (Lencer et al., 1993 ; Nambiar et al., 1993 ) and suggests that SV40 uses a novel entry pathway.
The sensitivity of a postsurface SV40 trafficking step to BFA treatment raised the possibility of Golgi complex involvement in the viral entry pathway. Inhibition of retrograde traffic between the Golgi complex and ER has been convincingly demonstrated by microinjection of an antibody to βCOP, a component of the coatomer complex of COPI-coated vesicles. Microinjection of anti-βCOP (EAGE) (Pepperkok et al., 1993 ) was found to inhibit COPI-mediated retrograde transport of the KDEL receptor and of ERGIC-53, both molecules that constitutively cycle between the ER and Golgi complex (Girod et al., 1999 ). Retrograde traffic of endocytosed CT-A subunit has also been found to be inhibited by anti-βCOP injection (Majoul et al., 1998 ; Girod et al., 1999 ). Vero cells were microinjected with anti-βCOP antibodies. Three to four hours later the cells were infected with SV40 for 21 h before fixation and immunolabeling for the microinjected antibody and T-ag. The microinjected antibodies showed cytosolic labeling and strong Golgi staining (Figure (Figure5A).5A). Quantitation of infection efficiency revealed a strong inhibition of viral infection in microinjected cells, compared with surrounding uninjected cells (Figure (Figure5B),5B), showing that the anti-βCOP antibody is a potent inhibitor of SV40 infection.
As a second independent method to inhibit COPI-mediated transport we used overexpression of a GTPase-deficient Arf1 mutant (Q71L). This mutant has previously been shown to inhibit COPI-dependent transport in the early secretory pathway (Dascher and Balch, 1994 ) and also to inhibit sorting and concentration of cargo molecules into COPI-coated vesicles in vitro (Lanoix et al., 1999 ). Vero cells were microinjected with either a mixture of Arf1(Q71L) and GFP expression plasmids or the GFP plasmid alone (as a control). After 5 h to allow expression of proteins the cells were incubated with SV40. Expression of Arf1(Q71L) in GFP-expressing cells injected with both plasmids was verified by immunolabeling the cells for βCOP. A clear disruption or complete disappearance of the Golgi βCOP labeling pattern in cells showing high levels of GFP expression was observed in cells injected with both plasmids but not in cells injected only with the GFP construct (Figure (Figure6,6, A–D). Quantitation of infection efficiency revealed a potent inhibition of SV40 infection in Arf1(Q71L)-expressing cells compared with neighboring nonexpressing cells. No such inhibition was observed in cells expressing GFP alone (Figure (Figure6E).6E).
In addition to their effects on COPI-mediated retrograde transport between the Golgi and ER, the dominant negative Arf1 mutant and microinjected βCOP antibody could also be affecting events early in endocytosis because Arf1 and COP proteins have been implicated in endosomal trafficking (Aniento et al., 1996 ; Daro et al., 1997 ; Gu et al., 1997 ; Gu and Gruenberg, 2000 ; Jackson and Casanova, 2000 ). To determine whether disruption of ER/Golgi transport could be responsible for inhibiting viral infection, we examined the effect of a selective inhibitor of ER/Golgi transport on SV40 infection by expression of the GTP-restricted mutant of Sar1, Sar1(H79G) (Aridor et al., 1995 ). We observed that cells coinjected with expression plasmids for GFP and Sar1(H79G) showed significant inhibition of SV40 infection (Figure (Figure6F).6F). Use of a temperature sensitive form of vesicular stomatitis virus glycoprotein (ts-045-G) confirmed that Sar1(H79G) and also Arf1(Q71L) were potently inhibiting anterograde transport in this system (Figure (Figure7).7). These results show a direct or indirect role for Arf1, Sar1, and COP-dependent trafficking steps in SV40 infection.
To further compare the CT and SV40 trafficking pathways, we examined the effect of the above-mentioned inhibitors on trafficking of CT-B to the Golgi complex or of CT holotoxin to the ER. Cells microinjected with plasmids encoding Arf1(Q71L) and Sar1(H79G) were incubated for 5 h and then allowed to bind and internalize CT-B-FITC for 40 min. A clear inhibition of toxin arrival at the Golgi was observed. The toxin was, however, internalized to early endosomes, although an obvious increase in intensity of cell-surface signal indicated a slight inhibition of entry (Figure (Figure8).8). A similar inhibition of CT internalization was elicited by microinjection of the anti-βCOP antibody (EAGE) (our unpublished data).
We then examined trafficking of CT holotoxin to the ER. Untreated cells showed that CT reached the ER in 2 h as judged by immunofluorescence (Figure (Figure9).9). Vero cells were injected with the above-mentioned constructs and protein expression was prevented by incubation with cycloheximide for 4 h. The cells were then allowed to bind and internalize CT holotoxin at 20°C for 1 h in the absence of cycloheximide. After subsequent incubation at 37°C for a further 2 h, the cells were fixed and immunolabeled for CT. This protocol allowed initial internalization of CT to endosomes at 20°C in the absence of mutant protein, but subsequent transport to the Golgi and ER at 37°C occurred in the presence of newly synthesized mutant proteins. As shown in Figure Figure9,9, the mutant proteins caused inhibition of transport to the ER with toxin accumulating in early endosomes (identified by colocalization with EEA1; our unpublished data) or perinuclear putative Golgi elements.
The inhibition of CT transport out of endosomes and to the Golgi by Arf1(Q71L) is in full accord with the previously described effect of BFA and could be explained by an Arf1/COPI-mediated transport step between endosomes and the Golgi complex. However, the similar inhibition by Sar1(H79G) can only be due to either disruption of the Golgi or a reliance of this endocytic pathway on a functional exocytic pathway.
To further compare SV40 infectious trafficking with the trafficking of CT to the ER and then cytosol, we investigated the effect of a recently described inhibitor of CT toxicity. The dipeptide benzyloxycarbonyl Cbz-gly-phe-NH2 causes a potent block in the late stages of toxin action and has no effect on the initial toxin entry step (De Wolf, 2000 ). This agent thus provides an important tool for comparing late stages in SV40 trafficking with those of CT.
Vero cells were preincubated for 1 h with 2 mM Cbz-gly-phe-NH2 or an inactive anolog, Cbz-gly-gly-NH2. The cells were then incubated for 21 h with SV40 in the continued presence of the same drug. Quantitation of T-ag expression efficiency revealed a potent inhibition of infection by Cbz-gly-phe-NH2 (Figure (Figure10A).10A). In contrast, the inactive analog Cbz-gly-gly-NH2 had no effect at the same concentration (Figure (Figure10A).10A). Infection was similarly inhibited in cells allowed to internalize the virus for 4 h before inactivation of surface-exposed SV40 (using the neutralizing antibody) and simultaneous exposure to the inhibitory dipeptide. This confirms an inhibition of the virus postentry (Figure (Figure10D).10D).
To assess whether the drug is specific for a retrograde trafficking pathway such as that followed by SV40 or CT, we examined its effects on infection by an enveloped virus, SFV. This virus enters cells by clathrin-mediated endocytosis and requires delivery to acidic endosomes for translocation to the cytosol and productive infection (Marsh et al., 1984 ). When Vero cells were exposed to recombinant SFV in the presence of the drug, no inhibitory effects on infection and expression of the SFV-encoded protein, caveolin-3 [SFV(cav-3)], were observed (Figure (Figure1010B).
As shown for the inhibition of CT toxicity, the effect of Cbz-gly-phe-NH2 on SV40 infection was found to be quickly reversible. Cells pretreated for 1 h before washing out the drug and infection with SV40 showed no inhibition of infection compared with untreated controls (our unpublished data). This suggests no lasting effects of the 1-h pretreatment. Furthermore, as observed for CT internalization, the block in SV40 infection appeared to be in late steps of the infectious pathway. A 21-h SV40 infection in the presence of the drug was followed by various periods of incubation in the absence of the drug before fixation and immunolabeling for T-ag. The percentage infection of treated cells stayed very low for the first 3 h after washing out the drug but began to recover after 6 h and reached control levels after 9 h (Figure (Figure10C).10C). This time period is shorter than that required for infection if virus is added to the outside of the cells and shows that the virus accumulates at a late stage in the infectious entry pathway. In keeping with this, electron microscopy of plastic sections revealed no detectable difference in the number of viral particles reaching ER cisternae in inhibitor- and control-treated cells (our unpublished data).
Finally, we examined CT trafficking in Cbz-gly-phe-NH2–treated cells. No inhibition of CT-B-FITC arrival to the Golgi was detected in inhibitor-treated cells, suggesting that only late events in the toxic entry pathway are affected (Figure (Figure11).11).
In conclusion, we have identified a potent new reversible inhibitor of SV40 infection that acts at a late stage in the infectious entry process. This makes Cbz-gly-phe-NH2 an invaluable tool for detailed characterization of these trafficking pathways.
The present study provides new insights into the pathway by which a simple nonenveloped virus, SV40, passes from the cell surface to its site of replication, the nucleus. This pathway involves transport from cell surface caveolae to a subdomain of the rough ER. We have examined this pathway morphologically and then proceeded to use specific inhibitors to disrupt the infectious entry pathway. We now show that the initial step in virus entry displays unique characteristics, being blocked by BFA and by incubation of cells at 20°C. We have also shown that the virus uses a pathway reliant on Arf1/COPI and Sar1 function to reach the ER. Finally, we have identified a novel inhibitor of viral infection, the dipeptide Cbz-gly-phe-NH2, known to block CT toxicity. These studies give fundamental new insights into the molecular mechanisms involved in this novel virus entry pathway.
SV40 infection proceeds via binding of the virus to MHC class I molecules on the cell surface (Breau et al., 1992 ) and then association with caveolae (Anderson et al., 1996 ; Stang et al., 1997 ; Chen and Norkin, 1999 ; Norkin, 1999 ; Parton and Lindsay, 1999 ; Pelkmans et al., 2001 ). The virus is then internalized but it is currently unknown whether the virus promotes internalization or follows the constitutive internalization of caveolae, still a contentious issue. We now show that the internalization step is blocked by BFA and by incubation at 20°C. This suggests a pathway distinct from other well-characterized internalization pathways and in particular, the constitutive entry of CT, a putative caveolar marker. Although the intracellular effects of BFA are well characterized, a role for BFA-sensitive Arf proteins in endocytic pathways at the plasma membrane has not been convincingly demonstrated. Endocytosis of CT, transferrin, and ricin have all been shown to be BFA independent (Lencer et al., 1993 ; Nambiar et al., 1993 ; Schonhorn and Wessling-Resnick, 1994 ; Uhlin-Hansen and Yanagishita, 1995 ). Similarly, incubation at 20°C does not inhibit CT entry and has commonly been used to accumulate ligands in early endosomes due to a block in traffic out of this compartment but not in initial internalization (Lencer et al., 1992 ; Mallard et al., 1998 ; Punnonen et al., 1998 ; Ren et al., 1998 ). Interestingly, a recent study of trafficking pathways used by various glycosyl phosphatidylinositol (GPI)-anchored proteins described a novel endocytic pathway displaying a similar sensitivity to incubation at 20°C as that of SV40 entry (Nichols et al., 2001 ). Such a pathway was shown to convey the raft-associated proteins, GPI-anchored GFP, and an endogenous GPI-anchored protein, CD59, from the plasma membrane to a nonclassical endosomal compartment and finally to the Golgi complex (Nichols et al., 2001 ). Another recent morphological study of the SV40 infectious pathway (Pelkmans et al., 2001 ) demonstrated internalization of the virus to a similarly nonclassical endosomal compartment termed by the authors, the “caveosome.” Common to the caveosome and the GPI-anchored protein-containing endosomal compartment is the absence of classical early endosomal markers such as EEA1 and internalized transferrin. In addition, Pelkmans et al. (2001) were able to demonstrate the lumenal pH of caveosomes to be neutral and also showed caveolin-1 to be a marker for this compartment. The possibility that inhibition of SV40 entry and GPI-anchored protein endocytosis at 20°C reflects an indirect effect of a block in plasma membrane delivery of key molecules trafficking through the secretory pathway rather than a direct effect on internalization still exists. Nevertheless, these pathways display key differences to known endocytic pathways and future studies will be aimed at dissecting the novel internalization mechanism.
The most striking finding of this study is that SV40 passes from the cell surface to its site of replication via a BFA-sensitive pathway dependent on Arf1/COPI function and Sar1 function. In parallel experiments, we have shown that intracellular trafficking of cholera toxin is also sensitive to BFA, disruption of Arf1/COPI function, and disruption of Sar1 function. The block in Golgi-to-ER transport of the toxin by microinjection of anti-βCOP (EAGE) has been previously described (Majoul et al., 1998 ). However, we herein demonstrate the inhibition of early endosome-to-Golgi transport of the toxin by BFA, βCOP antibodies, Arf1(Q71L), and Sar1(H79G). A similar inhibition of the transport of Shiga toxin (a related toxin) from early endosomes to the Golgi by BFA has been described previously (Mallard et al., 1998 ), but the discovery of Sar1 involvement in such a pathway is unprecedented and sheds new light on the possible mechanism of inhibition. One interpretation is that Arf1 and COPI coats assembling on early endosomes mediate toxin transport to the trans-Golgi network (because it is well known that Arf1 mediates assembly of COP proteins on early endosomal membranes as well as Golgi membranes; Aniento et al., 1996 ; Daro et al., 1997 ; Gu et al., 1997 ; Gu and Gruenberg, 2000 ; Jackson and Casanova, 2000 ). However, this does not explain Sar1(H79G)-mediated inhibition of the same step because the Sar1 GTPase is known to function only in ER-to-Golgi traffic (Aridor et al., 1995 ). Alternatively, because Arf1/COPI function and Sar1 function are both required for anterograde transport from the ER to Golgi (Aridor et al., 1995 ; Rowe et al., 1996 ; Pepperkok et al., 1998 ), it is feasible that early endosome-to-Golgi traffic is indirectly dependent on critical regulatory molecules delivered by a functional exocytic pathway. Such a dependence of endocytic pathways on a functional exocytic pathway could also explain accumulation of CT in early endosomes at 20°C, and inhibition of SV40 at the plasma membrane by BFA and at 20°C because exocytic traffic from the trans-Golgi network is inhibited at 20°C (Pepperkok et al., 1993 ). Whether this reflects a need for newly synthesized caveolin-1 at the cell surface for virus internalization remains to be determined.
It is important to note that subsequent to the initial entry of the virus, an intracellular step was also found to be inhibited by BFA. The affected trafficking step in the infectious pathway still remains unresolved; electron microscopic analysis of plastic sections has proven difficult due to dramatic alteration of the morphology of intracellular compartments by the inhibitory agents used (our unpublished data). It is also possible that BFA, βCOP antibodies, Arf1(Q71L), and Sar1(H79G) are all inhibiting retrograde transport of the virus from Golgi to ER. This is however inconsistent with the findings of the Pelkmans et al. (2001) study, which showed an absence of colocalization of Texas Red-labeled SV40 with Golgi markers at any time during infection. Instead, live fluorescence microscopy revealed the cointernalization of the virus with GFP-tagged caveolin-1 to the caveosome compartment from where the virus was sorted away from caveolin-1 and transported along microtubule tracks to a perinuclear compartment identified as the ER by colocalization with ER markers. Our studies provide additional tools for future characterization of this as yet poorly understood infectious pathway and the molecular machinery involved.
To further compare the properties of the SV40 and CT entry pathways, we used the dipeptide benzyloxycarbonyl Cbz-gly-phe-NH2, which has recently been demonstrated to inhibit late stages in CT toxicity (De Wolf, 2000 ). We now show that this drug, but not an inactive related dipeptide, is a potent and reversible inhibitor of SV40 infection. Initial characterization of the inhibition of SV40 infection showed that the drug is affecting a late stage of viral infection. Similarly, we found no apparent inhibition by the drug of early steps in uptake and delivery of CT-B-FITC to the Golgi compartment, confirming the observations of De Wolf. Infection by SFV, which enters cells via clathrin-coated pits and passes to acidic endosomal compartments before translocation to the cytosol, was completely unaffected by the drug, emphasizing the specificity of the inhibition for the SV40 and CT pathways. Also, production of the membrane protein SFV(cav-3) upon infection indicates that inhibition of protein translation was not occurring in these experiments, although such an effect of the drug has been described by others (Strous et al., 1988 ; Brostrom et al., 1991 ; Prostko et al., 1992 ). Similarly, expression of a cytosolic protein, GFP, under the SV40 promoter was found to be equally competent in treated and untreated cells (our unpublished data). Thus, the inhibition of T-ag expression after SV40 infection of treated cells cannot be attributed to an inhibition of protein translation. How does this dipeptide affect SV40 infection and is it acting in a similar manner to block both CT action and SV40 infection? Cbz-gly-phe-NH2 is a metalloprotease inhibitor but the drug is known to cause depletion of intracellular stores of calcium and lowers cytosolic calcium (Brostrom et al., 1991 ). This effect on calcium stores is thought to underlie its inhibition of membrane trafficking events between the ER and Golgi complex, and the Golgi complex and plasma membrane (Strous et al., 1988 ; Gravotta et al., 1990 ; Kuznetsov et al., 1992 ; Ivessa et al., 1995 ) and increasing extracellular levels of calcium has been found to rescue this inhibition (Kuznetsov et al., 1992 ). However, we have found that the inhibition of SV40 infection still occurs in the presence of elevated extracellular calcium levels (our unpublished data). Identical results were obtained for the inhibition of CT toxicity by Cbz-gly-phe-NH2 (De Wolf, 2000 ). This is suggestive of a common mechanism of inhibition of these two processes that differs from previously described effects of the drug. It has also been suggested that Cbz-gly-phe-NH2 may affect channels involved in CT transport to the cytosol (De Wolf, 2000 ). This hypothesis can now be tested and may render this drug a valuable tool for dissecting the enigmatic late steps in SV40 translocation.
In summary, we have identified hitherto unexpected COP-dependent trafficking steps involved in SV40 infection. The cellular machinery and the sorting mechanisms directing SV40 along this novel route now await dissection. The tools described herein should prove powerful in further efforts to dissect, and possibly exploit, this novel viral trafficking pathway.
We are indebted to Dr. Janet Butel for providing neutralizing antiserum to SV40 and to Dr. Juergen Kartenbeck for providing SV40 stocks. We are also grateful to members of the Parton laboratory for comments on the manuscript. This work was supported by a grant from the National Health and Medical Research Council of Australia (to R.G.P.) and was made possible by an equipment grant from the Wellcome Trust. A.A.R. is the holder of a University of Queensland Graduate School Research Travel Award. The Institute for Molecular Bioscience is a Special Research Center of the Australian Research Council.
Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.01–12–0592. Article and publication date are at www.molbiolcell.org/cgi/doi/10.1091/mbc.01–12–0592.